Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

bayer ag - aflibercept - solution for injection - 40mg/ml

Israel - English - Ministry of Health

bayer israel ltd - aflibercept - solution for intravitreal injection - aflibercept 40 mg/ml - aflibercept - eylea is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (amd)• visual impairment due to macular oedema secondary to retinal vein occlusion (branch crvo or central rvo)• visual impairment due to diabetic macular oedema (dme)• visual impairment due to myopic choroidal neovascularisation (myopic cnv).

European Union - English - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - ophthalmologicals - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5.1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5.1),visual impairment due to diabetic macular oedema (dme) (see section 5.1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.1).

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

ranibizumab 10mg/ml

Canada - English - Health Canada

bayer inc - aflibercept - solution - 2mg - aflibercept 2mg - eent drugs, miscellaneous

Canada - English - Health Canada

bayer inc - aflibercept - solution - 2mg - aflibercept 2mg - eent drugs, miscellaneous

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - aflibercept 40 mg/ml;   - solution for injection - 40 mg/ml - active: aflibercept 40 mg/ml   excipient: dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 20 sodium chloride sucrose water for injection - eylea (aflibercept) is indicated for the treatment of: · neovascular (wet) age-related macular degeneration (wet amd) · visual impairment due to macular oedema secondary to central retinal vein occlusion (crvo) · visual impairment due to macular oedema secondary to branch retinal vein occlusion (brvo) · diabetic macular oedema (dme) · visual impairment due to myopic choroidal neovascularisation (myopic cnv)

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - aflibercept, quantity: 40 mg/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; dibasic sodium phosphate heptahydrate; sucrose; water for injections; polysorbate 20 - eylea (aflibercept) is indicated in adults for the treatment of: - neovascular (wet) age-related macular degeneration (wet amd) - visual impairment due to macular oedema secondary to central retinal vein occlusion (crvo) - diabetic macular oedema (dme) - visual impairment due to macular oedema secondary to branch retinal vein occlusion (brvo) - visual impairment due to myopic choroidal neovascularisation (myopic cnv)

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - aflibercept, quantity: 40 mg/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sucrose; polysorbate 20; sodium chloride; water for injections; dibasic sodium phosphate heptahydrate - eylea (aflibercept) is indicated in adults for the treatment of: - neovascular (wet) age-related macular degeneration (wet amd); - visual impairment due to macular oedema secondary to central retinal vein occlusion (crvo); - diabetic macular oedema (dme); - visual impairment due to macular oedema secondary to branch retinal vein occlusion (brvo); - visual impairment due to myopic choroidal neovascularisation (myopic cnv)

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - aflibercept -